Affordable Access

Publisher Website

Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1phototherapy

Authors
Journal
Journal of the American Academy of Dermatology
0190-9622
Publisher
Elsevier
Volume
42
Issue
1
Identifiers
DOI: 10.1016/s0190-9622(00)90023-9
Disciplines
  • Medicine

Abstract

Abstract Graft-versus-host disease is a frequent complication of allogenic bone marrow transplantation. Approximately 10% of patients suffering from chronic graft-versus-host disease develop sclerodermic graft-versus-host disease of the skin, which often does not respond to conventional immunosuppressive therapy. An alternative to immunosuppressive treatment is photochemotherapy. We describe a patient with chronic sclerodermic graft-versus-host disease who did not respond to a combination therapy of cyclosporine and prednisone and later mycophenolate mofetil plus prednisone. A combination therapy of mycophenolate mofetil (2 g/day) and low-dose UVA1 therapy (single dose, 20 J/cm2, 4 times per week over 6 weeks) resulted in striking clinical improvement of sclerodermic graft-versus-host disease. (J Am Acad Dermatol 2000;42:134-6.)

There are no comments yet on this publication. Be the first to share your thoughts.